Superbug sleuths decode the DNA of drug-resistant e. coli to stop its spread
NCT ID NCT07676513
First seen Jun 30, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This study examines the genetic makeup of carbapenem-resistant E. coli bacteria collected from patients in southern France. Researchers will sequence the bacteria's full genomes to identify different strains, resistance genes, and virulence factors. The goal is to understand how these superbugs are evolving and spreading, which could improve detection and infection control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could reveal how resistant E. coli spreads and help design better detection and control strategies.
- What could go wrong
- This is an observational study analyzing existing bacterial samples, not testing a new treatment. Findings may not apply to other regions or lead directly to clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBIOTIC RESISTANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nîmes University Hospital
Nîmes, Gard, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibiotic combo beat Drug-Resistant urinary infections in the blood?
- Probiotics join the fight against superbugs in the gut
- Fungal fingerprints in lungs may predict ABPA Flare-Ups
- Could a common antibiotic spare Last-Resort drugs for ICU lung infections?
- Poop pills aim to wipe out superbugs in the gut
- Old heart drug takes on superbugs in cancer patients